Mirtazapine: Difference between revisions
No edit summary |
|||
| Line 45: | Line 45: | ||
===Side effects occurring commonly:=== |
===Side effects occurring commonly:=== |
||
* Increased [[appetite]] |
* Increased [[appetite]].... |
||
* Vivid dreams/ [[Nightmares]] as a result of regular intake |
* Vivid dreams/ [[Nightmares]] as a result of regular intake |
||
* Weight gain |
* Weight gain |
||
Revision as of 18:27, 30 July 2007
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral tablet, Solulable tablet |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 50% |
| Metabolism | Liver |
| Elimination half-life | 37 hours (females), 26 hours (males) |
| Excretion | 75% urine 15% feces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.080.027 |
| Chemical and physical data | |
| Formula | C17H19N3 |
| Molar mass | 265.36 g·mol−1 |
Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of mild to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic effects, serotonin-related side effects,[1] and adrenergic side effects (orthostatic hypotension and sexual dysfunction). Antihistaminic side effects of drowsiness and weight gain are prominent. It is most useful as an add on medication to enhance the effectiveness of agents such as duloxetine and venlafaxine in severe and treatment resistant depression. Mirtazapine is relatively safe if an overdose is taken.[2]
Trade Names
Mirtazapine is marketed under the tradenames Remeron® in the U.S., Canada, Brazil, Israel, Finland, Norway Netherlands, Italy, Sweden, Switzerland and Czech Republic, Avanza® and Axit® in Australia, Zispin® in the UK & Ireland, Norset® in France, Remergon® in Belgium, Remergil® in Germany, Mirtabene® in Austria, Mirtaz® in India and Srilanka, Rexer® in Spain and Promyrtil in Chile.
Indications
Approved
Mirtazapine is primarily used to treat the symptoms of mild to severe depression.[3]
Unapproved/Off-label/Investigational
There is also evidence that mirtazapine can be used to treat panic disorder (PD),[4] generalized anxiety disorder (GAD),[5] obsessive-compulsive disorder (OCD),[6] post traumatic stress disorder (PTSD)[7] and pruritus.[8] Mirtazapine has not been reported to be effective in the prophylactic treatment of chronic tension headache.[9]
Veterinary
Anecdotal evidence also suggests that mirtazapine may be effective in treating certain vomiting or anorexia-related conditions in dogs and cats. Any such use is still off-label, however.
Mechanism of action
It is thought to work by blocking presynaptic alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin, thereby increasing active levels in the synapse. Mirtazapine also blocks post-synaptic 5-HT2 and 5-HT3 receptors—an action which is thought to enhance serotonergic neurotransmission while causing a low incidence of side effects.[citation needed]
Side effects
Interestingly, its side effect profile can be used for benefit in certain clinical situations. The drowsiness, increased appetite, and weight gain it causes are useful in patients with depressive disorders with prominent sleep and appetite disturbances. In addition, it is quite useful in patient situations in which patients suffer from nausea since it also antagonizes the 5-HT3 receptor, the target of the popular anti-emetic ondansetron (Zofran®).
At lower dosages, such as 7.5 mg, mirtazapine is primarily antihistaminergic, causing sedation, which can be beneficial in depressed patients who have difficulty falling asleep. At doses higher than 15 mg, its effect is primarily in inducing the release of norepinephrine, and is thus less sedating.[citation needed]
Side effects occurring commonly:
- Increased appetite....
- Vivid dreams/ Nightmares as a result of regular intake
- Weight gain
- Increase in cholesterol, independent of weight gain
- Drowsiness, especially at lower doses and during the first few weeks of treatment
- Dizziness, coupled often with the effects of sickness
- Headache
- General or local swelling
- Visual hallucinations (when taken during the day or when awake)
Side effects occurring rarely:
- Excessive urinating when taken with alcohol
- Mania
- Seizures
- Tremor
- Muscle twitching and Restless Legs Syndrome
- Pins and needles
- Rash and skin eruptions
- Pain in the joints or muscles
- Low blood pressure
- Higher blood pressure
- Causes obesity
Dangerous side effects
If you experience any of these, tell your doctor immediately. You will need to consult your doctor for taper-off instructions. Sudden withdrawal from antidepressants can cause serious symptoms.
- An allergic reaction; signs of swelling of the lips, face and tongue, difficulty in breathing, rash or itching (especially affecting the whole body) or feeling faint.
- Signs of infection such as fever, sore throat, mouth ulcers or stomach upset.
- Jaundice (yellowing of the skin and/or eyes).
- Agranulocytosis
Dosage
The usual starting dose for mirtazapine is 15 mg once daily, usually at bedtime (because of its sedative nature and the possibility of disturbed visual perception). Doses may be increased, following medical advice, every 1-2 weeks up to a dose of 45 mg. It may be taken with or without food. Dissolving tablets (SolTab® orally disintegrating tablets) can even be taken without water.
Pregnancy and Lactation
- Pregnancy : Sufficient data in humans is lacking. The use should be justified by the severity of the condition to be treated.
- Lactation : Sufficient data in humans is also lacking. Additionally, Mirtazapine may be found in the maternal milk in significant concentrations. The use in breastfeeding women should be carefully weighed against possible risks.
Drug-Drug Interactions
Because of the sedative effects of Mirtazapine, excessive sedation may result when it is used with other sedating substances, such as alcohol or benzodiazepines. According to official prescribing information from Organon, mirtazapine should not be used within 14 days of the use of an MAOI because of the risk of serious effects such as hypertensive emergency and hyperthermia. However, MAOI experts generally consider them safe to use with mirtazapine, with proper monitoring.
External links
References
- ^ Gillman, PK (2006). "A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status". Human Psychopharmacology Clinical and Experimental. 21 (2): 117–25. PMID 16342227.
- ^ Burrows GD, Kremer CM. (1997). "Mirtazapine: clinical advantages in the treatment of depression". Journal of Clinical Psychopharmacology. 17 (2S): 34S–39S. PMID 9090576.
- ^ Velazquez C, Carlson A, Stokes KA, Leikin JB. (2001). "Relative safety of mirtazapine overdose". Veterinary and Human Toxicology. 43 (6): 342–344. PMID 11757992.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Gorman JM (1999). "Mirtazapine: clinical overview". Journal of Clinical Psychiatry. 60 (17): 9–13. PMID 10446735.
- ^ Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 19 (6): 567–596. PMID 16272179.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Goodnick PJ, Puig A, DeVane CL, Freund BV (1999). "Mirtazapine in major depression with comorbid generalized anxiety disorder". Journal of Clinical Psychiatry. 60 (7): 446–448. PMID 10453798.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN (2005). "Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation". Journal of Clinical Psychiatry. 66 (4): 515–520. PMID 15816795.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU (2005). "Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 19 (6): 567–596. PMID 16272179.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Davis MP, Frandsen JL, Walsh D, Andresen S, Taylor S. (2003). "Mirtazapine for pruritus". Journal of pain and symptom management. 25 (3): 288–291. PMID 12614964.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Bendtsen L, Jensen R (2004). "Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache". Neurology. 62 (10): 1706–1711. PMID 15159466.
- ^ Gillman, PK (2006). "A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status". Human Psychopharmacology Clinical and Experimental. 21 (2): 117–25. PMID 16342227.
- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.